Last 12 months
Inside the activity.
0 purchase rows · 36 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 30 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
Hunt NimrataExecutive Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 162 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · derivative · entry 9 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162 Underlying: Common Stock · 162 shares Expires 2036-02-11 F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
Hunt NimrataExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 4,625 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · derivative · entry 8 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,625 Underlying: Common Stock · 4,625 shares Expires 2036-02-11 F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
Lane MichaelExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 1,620 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000023 · wk-form4_1771374647.xml · derivative · entry 10 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,620 Underlying: Common Stock · 1,620 shares Expires not disclosed F9 · derivative.exercise_price: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in three annual installments, beginning February 14, 2027. F9 · derivative.exercise_date: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in three annual installments, beginning February 14, 2027. F9 · derivative.expiration_date: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in three annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
Lane MichaelExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 1,262 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000023 · wk-form4_1771374647.xml · derivative · entry 9 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,262 Underlying: Common Stock · 1,262 shares Expires not disclosed F8 · derivative.exercise_price: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. F8 · derivative.exercise_date: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. F8 · derivative.expiration_date: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
Lane MichaelExecutive Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 162 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000023 · wk-form4_1771374647.xml · derivative · entry 8 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162 Underlying: Common Stock · 162 shares Expires 2036-02-11 F7 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
Lane MichaelExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 5,361 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000023 · wk-form4_1771374647.xml · derivative · entry 7 Lane Michael · CIK 0001740689 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,361 Underlying: Common Stock · 5,361 shares Expires 2036-02-11 F6 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
FENNELL GEORGEExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 810 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 8 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 810 Underlying: Common Stock · 810 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F4 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F4 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
FENNELL GEORGEExecutive Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 162 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 7 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162 Underlying: Common Stock · 162 shares Expires 2036-02-11 F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
FENNELL GEORGEExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 3,384 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 6 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,384 Underlying: Common Stock · 3,384 shares Expires 2036-02-11 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
Erickson Michael GExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 1,580 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · derivative · entry 9 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,580 Underlying: Common Stock · 1,580 shares Expires not disclosed F6 · derivative.exercise_price: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. F6 · derivative.exercise_date: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. F6 · derivative.expiration_date: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
Erickson Michael GExecutive Vice President
|
GrantRestricted Stock Unit · Derivative | 4,739 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000019 · wk-form4_1771374615.xml · derivative · entry 8 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,739 Underlying: Common Stock · 4,739 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
Emerson AndrewEVP, CFO and Treasurer
|
Exercise / conversionRestricted Stock Unit · Derivative | 65 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 11 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193 Underlying: Common Stock · 65 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan. F9 · derivative.exercise_date: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan. F9 · derivative.expiration_date: Represents RSUs that were granted on February 14, 2025 and deferred in accordance with the Issuer's Deferred Compensation Plan and represents a contingent right to receive one share of Issuer common stock vesting in four annual installments, beginning February 14, 2026. Upon vesting, each such RSU will be recorded in an account under such Plan. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
Emerson AndrewEVP, CFO and Treasurer
|
GrantRestricted Stock Unit · Derivative | 284 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 10 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284 Underlying: Common Stock · 284 shares Expires not disclosed F8 · derivative.exercise_price: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. F8 · derivative.exercise_date: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. F8 · derivative.expiration_date: Grant of RSUs that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
Emerson AndrewEVP, CFO and Treasurer
|
GrantRestricted Stock Unit · Derivative | 729 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 9 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 729 Underlying: Common Stock · 729 shares Expires not disclosed F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
Emerson AndrewEVP, CFO and Treasurer
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 162 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 8 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162 Underlying: Common Stock · 162 shares Expires 2036-02-11 F6 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC |
Emerson AndrewEVP, CFO and Treasurer
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 4,270 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000018 · wk-form4_1771374607.xml · derivative · entry 7 Emerson Andrew · CIK 0002058587 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,270 Underlying: Common Stock · 4,270 shares Expires 2036-02-11 F5 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Mar 4, 2026 02:45 UTC Amendment |
Erickson Michael GExecutive Vice President
|
GrantIncentive Stock Option (right-to-buy) · Derivative | 162 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000046 · wk-form4a_1772592318.xml · derivative · entry 3 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162 Underlying: Common Stock · 162 shares Expires 2036-02-11 F2 · security: This Amendment on Form 4/A (this 'Amendment') amends the Form 4 filed on February 17, 2026 (the 'Original Form 4') solely to correct an administrative error, which resulted in the inadvertent erroneous reporting of the equity awards granted to the reporting person on February 12, 2026. Specifically, Table II of the Original Form 4 incorrectly reported that 6,319 restricted stock units (of which 1,580 restricted stock units were deferred) were granted to the reporting person on February 12, 2026, which did not occur. Instead, as reported in this Amendment, a non-qualified stock option to purchase 13,667 shares of Issuer common stock and an incentive stock option to purchase 162 shares of Issuer common stock were granted to the reporting person on February 12, 2026, with an exercise price equal to the closing price of the Issuer's common stock on that day. This Amendment does make any other changes to the Original Form 4. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. Read SEC document |
| February 12, 2026 Filed Mar 4, 2026 02:45 UTC Amendment |
Erickson Michael GExecutive Vice President
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 13,667 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000046 · wk-form4a_1772592318.xml · derivative · entry 2 Erickson Michael G · CIK 0002005385 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,667 Underlying: Common Stock · 13,667 shares Expires 2036-02-11 F2 · security: This Amendment on Form 4/A (this 'Amendment') amends the Form 4 filed on February 17, 2026 (the 'Original Form 4') solely to correct an administrative error, which resulted in the inadvertent erroneous reporting of the equity awards granted to the reporting person on February 12, 2026. Specifically, Table II of the Original Form 4 incorrectly reported that 6,319 restricted stock units (of which 1,580 restricted stock units were deferred) were granted to the reporting person on February 12, 2026, which did not occur. Instead, as reported in this Amendment, a non-qualified stock option to purchase 13,667 shares of Issuer common stock and an incentive stock option to purchase 162 shares of Issuer common stock were granted to the reporting person on February 12, 2026, with an exercise price equal to the closing price of the Issuer's common stock on that day. This Amendment does make any other changes to the Original Form 4. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC |
FENNELL GEORGEExecutive Vice President
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 11,345 | $0.00 Strike: $67.85 | $0.00 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · derivative · entry 12 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,345 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Grant of option to buy 11,345 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2017. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC |
FENNELL GEORGEExecutive Vice President
|
SaleCommon Stock | 40 | $650.32 | $26,012.80 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 10 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,823 Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC |
FENNELL GEORGEExecutive Vice President
|
SaleCommon Stock | 2,809 | $649.26 | $1,823,771.06 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 9 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,863 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $649.05 to a high of $649.72 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC |
FENNELL GEORGEExecutive Vice President
|
SaleCommon Stock | 966 | $648.78 | $626,720.71 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 8 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,672 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $648.02 to a high of $649.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC |
FENNELL GEORGEExecutive Vice President
|
SaleCommon Stock | 1,060 | $647.21 | $686,039.00 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 7 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,638 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $646.825 to a high of $647.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC |
FENNELL GEORGEExecutive Vice President
|
SaleCommon Stock | 2,782 | $646.23 | $1,797,800.45 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 6 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,698 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $645.80 to a high of $646.71 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC |
FENNELL GEORGEExecutive Vice President
|
SaleCommon Stock | 2,161 | $645.25 | $1,394,387.84 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 5 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,480 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $644.75 to a high of $645.60 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC |
FENNELL GEORGEExecutive Vice President
|
SaleCommon Stock | 397 | $644.02 | $255,674.35 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 4 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,641 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $643.65 to a high of $644.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC |
FENNELL GEORGEExecutive Vice President
|
SaleCommon Stock | 1,130 | $643.00 | $726,587.06 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 3 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,038 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $642.595 to a high of $643.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:01 UTC |
FENNELL GEORGEExecutive Vice President
|
Exercise / conversionCommon Stock | 11,345 | $67.85 | $769,758.25 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 2 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:01 UTC |
FENNELL GEORGEExecutive Vice President
|
Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,476 | $0.00 Strike: $67.85 | $0.00 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · derivative · entry 11 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,476 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Grant of option to buy 1,476 shares of Issuer common stock that vested on February 14, 2021. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:01 UTC |
FENNELL GEORGEExecutive Vice President
|
Exercise / conversionCommon Stock | 1,476 | $67.85 | $100,146.60 |
DisclosureSEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 1 FENNELL GEORGE · CIK 0001521861 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 22:01 UTC |
HOOLEY JOSEPH LDirector
|
GrantCommon Stock | 36 | $670.46 | $24,136.56 |
DisclosureSEC source: 0000874716-26-000002 · wk-form4_1770156063.xml · nonDerivative · entry 1 HOOLEY JOSEPH L · CIK 0001123847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($24,375.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock as soon as practicable following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:01 UTC |
Peacock KarenDirector
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 231 | $0.00 Strike: $727.97 | $0.00 |
DisclosureSEC source: 0000874716-25-000170 · wk-form4_1764799274.xml · derivative · entry 2 Peacock Karen · CIK 0001786299 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231 Underlying: Common Stock · 231 shares Expires 2035-11-30 F1 · security: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from the date of her election to the IDEXX Laboratories, Inc. Board of Directors on October 6, 2025 until the 2026 annual meeting of stockholders. F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests in one installment on May 7, 2026 or on the date of the 2026 annual meeting of stockholders, whichever event is earlier. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:01 UTC |
Peacock KarenDirector
|
GrantRestricted Stock Unit · Derivative | 101 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000170 · wk-form4_1764799274.xml · derivative · entry 1 Peacock Karen · CIK 0001786299 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101 Underlying: Common Stock · 101 shares Expires not disclosed F1 · security: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from the date of her election to the IDEXX Laboratories, Inc. Board of Directors on October 6, 2025 until the 2026 annual meeting of stockholders. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in one installment on May 7, 2026 or on the date of the 2026 annual meeting of stockholders, whichever event is earlier. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in one installment on May 7, 2026 or on the date of the 2026 annual meeting of stockholders, whichever event is earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in one installment on May 7, 2026 or on the date of the 2026 annual meeting of stockholders, whichever event is earlier. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC |
Hunt NimrataExecutive Vice President
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 5,405 | $0.00 Strike: $505.53 | $0.00 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · derivative · entry 9 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,604 Underlying: Common Stock · 5,405 shares Expires 2032-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC |
Hunt NimrataExecutive Vice President
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 7,125 | $0.00 Strike: $288.78 | $0.00 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · derivative · entry 8 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,125 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested in four annual installments beginning February 14, 2021. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC |
Hunt NimrataExecutive Vice President
|
SaleCommon Stock | 1,378 | $705.54 | $972,240.73 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · nonDerivative · entry 6 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,148.9435 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $705.26 to a high of $705.92 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC |
Hunt NimrataExecutive Vice President
|
SaleCommon Stock | 1,468 | $704.87 | $1,034,743.14 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · nonDerivative · entry 5 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,526.9435 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $704.235 to a high of $705.175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC |
Hunt NimrataExecutive Vice President
|
SaleCommon Stock | 1,465 | $703.73 | $1,030,970.16 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · nonDerivative · entry 4 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,994.9435 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $703.05 to a high of $703.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC |
Hunt NimrataExecutive Vice President
|
SaleCommon Stock | 5,114 | $702.20 | $3,591,059.49 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · nonDerivative · entry 3 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,459.9435 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $702.00 to a high of $703.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC |
Hunt NimrataExecutive Vice President
|
Exercise / conversionCommon Stock | 5,405 | $505.53 | $2,732,389.65 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · nonDerivative · entry 2 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,573.9435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC |
Hunt NimrataExecutive Vice President
|
Exercise / conversionCommon Stock | 7,125 | $288.78 | $2,057,557.50 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,168.9435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 11 shares purchased under the Issuer Employee Stock Purchase Plan on September 30, 2025. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:00 UTC |
HOOLEY JOSEPH LDirector
|
GrantCommon Stock | 39 | $628.54 | $24,513.06 |
DisclosureSEC source: 0000874716-25-000166 · wk-form4_1762207212.xml · nonDerivative · entry 1 HOOLEY JOSEPH L · CIK 0001123847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the 'Plan') in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($24,375.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock as soon as practicable following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 21:56 UTC |
Smith Martin AlexanderExecutive Vice President
|
Exercise / conversionRestricted Stock Unit · Derivative | 18 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-25-000150 · wk-form4_1756936587.xml · derivative · entry 3 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning September 1, 2022. F4 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning September 1, 2022. F3 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning September 1, 2022. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 21:56 UTC |
Smith Martin AlexanderExecutive Vice President
|
Tax withholdingCommon Stock | 5 | $647.09 | $3,235.45 |
DisclosureSEC source: 0000874716-25-000150 · wk-form4_1756936587.xml · nonDerivative · entry 2 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,433.659 F2 · price: Closing price of Issuer common stock on the Nasdaq Global Select Market on August 29, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 21:56 UTC |
Smith Martin AlexanderExecutive Vice President
|
Exercise / conversionCommon Stock | 18 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000150 · wk-form4_1756936587.xml · nonDerivative · entry 1 Smith Martin Alexander · CIK 0001621358 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,438.659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 28.709 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 21:55 UTC |
HOOLEY JOSEPH LDirector
|
GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 364 | $0.00 Strike: $647.09 | $0.00 |
DisclosureSEC source: 0000874716-25-000149 · wk-form4_1756936544.xml · derivative · entry 2 HOOLEY JOSEPH L · CIK 0001123847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364 Underlying: Common Stock · 364 shares Expires 2035-08-31 F1 · security: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from his election to the IDEXX Laboratories, Inc. Board of Directors on July 10, 2025 until the 2026 annual meeting of stockholders. F3 · derivative.exercise_price: Closing price of Issuer common stock on the Nasdaq Global Select Market on August 29, 2025. F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests in one installment on May 7, 2026 or on the date of the 2026 annual meeting of stockholders, whichever event is earlier. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 21:55 UTC |
HOOLEY JOSEPH LDirector
|
GrantRestricted Stock Unit · Derivative | 158 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000149 · wk-form4_1756936544.xml · derivative · entry 1 HOOLEY JOSEPH L · CIK 0001123847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158 Underlying: Common Stock · 158 shares Expires not disclosed F1 · security: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from his election to the IDEXX Laboratories, Inc. Board of Directors on July 10, 2025 until the 2026 annual meeting of stockholders. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in one installment on May 7, 2026 or on the date of the 2026 annual meeting of stockholders, whichever event is earlier. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in one installment on May 7, 2026 or on the date of the 2026 annual meeting of stockholders, whichever event is earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in one installment on May 7, 2026 or on the date of the 2026 annual meeting of stockholders, whichever event is earlier. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 21:00 UTC |
SZOSTAK M ANNEDirector
|
Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 2,187 | Not disclosed Strike: $206.62 | Not disclosed |
DisclosureSEC source: 0000874716-25-000146 · wk-form4_1756242006.xml · derivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,187 shares Expires 2028-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event was earlier. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 21:00 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 259 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000146 · wk-form4_1756242006.xml · nonDerivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The O'Hanian-Szostak Family Foundation Disclosed balance after: 259 F3 · ownership.nature: The reporting person is a trustee of The O'Hanian-Szostak Family Foundation ('Foundation') and has power to direct the distribution of assets held by the Foundation. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 21:00 UTC |
SZOSTAK M ANNEDirector
|
GiftCommon Stock | 259 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000146 · wk-form4_1756242006.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 1,542 F2 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.